Abstract:Objective:To compare the efficacy and safety of risperidone and chlorpromazine in treatment of first-episode schizo phrenia.Methods:It is a one year naturalistic study.One hundred and eighty-six patients with first-episode of schizophrenia were included who met ICD-10 criteria for schizophrenia or schizophreniform disorder and received integrated treatment(risper- idone or chlorpromazine plus psychosocial education,family psycho-education).There were 131 patients included in the risperi- done group and 55 included in the chlorpromazine group.Written informed consent was obtained from the patients or their legal guardians.Clinical stains was assessed with the Positive and Negative Symptom Scale(PANSS).the Treatment Emergent Symptom Scale(TESS)and the time to the discontinuation of treatment.The Short Form-36(sf-36)was used to assess the quality of life.Results:Thirty-five percent in the rieperdone group partially completed follow-up assessments and 51% in the chlor promazine group did.the difference of the rates between the two groups was significant.Response rate was defined as improvement in PANSS total score of≥50%.The response rates at the end of 2.3.6.8.12 months in the risperidone group were 29.1%.41.8%. 50.9%.50.9%.56.4% and in the chlorpromazine group were 40.5%.46.6%.57.3%.64.1%.62.6%.respectively.There was no significant difference of the response rate at any of the follow up time between the two groups.The relapse rates were similar as 20. 2% in the risperidone group and 20.6% in the comparing group.The time to the discontinuation of treatment for any cause was longer in the risperidone group than in the chlorpromazine gronp.However.the difference was not significant.Risperidone was associated with lower symptoms of tremor,constipation,sialorrhea(P0.01)and also associated with more frequent reports of agitation,de- pression,insomnia,gastrointestinal disturbance,menstrual disorder(P0.05).There are significant improvements in 6 factors (role of physics,body pain.globe health,social function,role of emotion and mental heahh)of sf 36 in risperidone group and only 2 factory(social function,role of emotion)in the comparative group.Conclusion:The efficacy of risperidone is as same as that of chlorpromazine in the treatment of first-episode schizophrenia,yet the rates of some adverse events are different in the two groups and risperidone may enhance the quality of life from more aspects.

Open Observation and Control Study of the Efficacy and Safety of Paliperi-done Extended-release Tablets and Risperidone Tablets in the Treatment of First-episode Schizophrenia

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

A clinical controlled study on schizophrenia treated with paliperidone-ER and risperidone

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Clinical study on the efficacy of paliperidone extended-release tablets in the treatment of schizophrenia outpatients and its effect on social function

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Study on Efficacy and Safety of Risperidone in Treatment of Different Kinds of Schizophrenia

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis.

A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia

A Control Study on Aripiprazole and Risperidone in the Treatment of Schizophrenia.

Clinical Efficacy and Patient Satisfaction Evaluation in Acute Schizophrenia with Paliperidone Extended Release Therapy

An open-label clinical trial of paliperidone in the treatment of schizophrenia in children and adolescents

One Year Follow-up Study: Risperidone and Chlorpromazine for Patients with First-episode Schizophrenia

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study.

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

Observation on Clinical Efficacy of Risperidone in Treatment of Children and Adolescents with Schizophrenia

Clinical Study of Risperidone Orally Disintegrating Tabiets and Clozapine in the Treatment of Schizophrenia

The Efficacy and Safety of Flexible Doses of Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: a Randomized, Double Blind Olanzapine-Controlled Study